Paper37596643
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Glaviano A and 26 others. Mol Cancer, 2023. Cited by 1,779 papers, by iCite.
Cite this record
ConductScience Library. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Papers, record 37596643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37596643
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Phosphatidylinositol 3-Kinases | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Proto-Oncogene Proteins c-akt | |
| Signal Transduction | |
| TOR Serine-Threonine Kinases |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | Background |
Source ClinicalTrials.gov
References426
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15930273 | Functional analysis of PIK3CA gene mutations in human colorectal cancer. | Cancer Res | 2005 | https://conductscience.org/library/papers/15930273 | PubMed |
| 2 | 27826244 | Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. | Front Pharmacol | 2016 | https://conductscience.org/library/papers/27826244 | PubMed |
| 3 | 35250965 | mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment. | Front Immunol | 2021 | https://conductscience.org/library/papers/35250965 | PubMed |
| 4 | 22722201 | The landscape of cancer genes and mutational processes in breast cancer. | Nature | 2012 | https://conductscience.org/library/papers/22722201 | PubMed |
| 5 | 32451180 | Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. | Eur Urol | 2020 | https://conductscience.org/library/papers/32451180 | PubMed |
| 6 | 34320785 | Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. | Haematologica | 2022 | https://conductscience.org/library/papers/34320785 | PubMed |
| 7 | 25488966 | Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25488966 | PubMed |
| 8 | 16341149 | The Akt pathway in human breast cancer: a tissue-array-based analysis. | Mod Pathol | 2006 | https://conductscience.org/library/papers/16341149 | PubMed |
| 9 | 35484662 | Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis. | Haematologica | 2022 | https://conductscience.org/library/papers/35484662 | PubMed |
| 10 | 35118422 | The present and future of PI3K inhibitors for cancer therapy. | Nat Cancer | 2021 | https://conductscience.org/library/papers/35118422 | PubMed |
| 11 | 27097161 | Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway. | PLoS One | 2016 | https://conductscience.org/library/papers/27097161 | PubMed |
| 12 | 26403194 | Regulation of innate immune cell function by mTOR. | Nat Rev Immunol | 2015 | https://conductscience.org/library/papers/26403194 | PubMed |
| 13 | 19644473 | Targeting the phosphoinositide 3-kinase pathway in cancer. | Nat Rev Drug Discov | 2009 | https://conductscience.org/library/papers/19644473 | PubMed |
| 14 | 36646410 | The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer. | Cancer Lett | 2023 | https://conductscience.org/library/papers/36646410 | PubMed |
| 15 | 14598361 | Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. | J Surg Oncol | 2003 | https://conductscience.org/library/papers/14598361 | PubMed |
| 16 | 37311901 | Capivasertib delays disease progression. | Nat Rev Clin Oncol | 2023 | https://conductscience.org/library/papers/37311901 | PubMed |
| 17 | 26703889 | Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. | Lancet | 2016 | https://conductscience.org/library/papers/26703889 | PubMed |
| 18 | 33175607 | Long non-coding RNA IGF2-AS represses breast cancer tumorigenesis by epigenetically regulating IGF2. | Exp Biol Med (Maywood) | 2021 | https://conductscience.org/library/papers/33175607 | PubMed |
| 19 | 21878902 | Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. | Mol Ther | 2011 | https://conductscience.org/library/papers/21878902 | PubMed |
| 20 | 33352201 | Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial. | Ann Oncol | 2021 | https://conductscience.org/library/papers/33352201 | PubMed |
Cited by1,345
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,779 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42978971 | Crosstalk between PI3K/AKT signaling and epigenetic regulation in hepatocellular carcinoma: molecular mechanisms and therapeutic opportunities. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42978971 | PubMed |
| 42976151 | Exogenous tryptophan aggravates experimental lung fibrosis through activation of AKT-mTORC1 pathway. | PLoS One | 2026 | https://conductscience.org/library/papers/42976151 | PubMed |
| 42967165 | Unraveling the EMT Spectrum in Aggressive Breast Cancer: Bridging Molecular Hybrid States with Functional Assay Interpretation. | Onco Targets Ther | 2026 | https://conductscience.org/library/papers/42967165 | PubMed |
| 42959329 | Macrophage lipophagy in atherosclerosis: from molecular mechanisms to traditional Chinese medicine interventions. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42959329 | PubMed |
| 42958602 | Glioblastoma as a dynamic tumor ecosystem: from molecular alterations to therapeutic translation. | Exp Hematol Oncol | 2026 | https://conductscience.org/library/papers/42958602 | PubMed |
| 42958312 | The effects of root decay on the anti-tumor potential of Scutellariae Radix: an investigation using mass spectrometry imaging, network pharmacology and in vitro validation. | BMC Complement Med Ther | 2026 | https://conductscience.org/library/papers/42958312 | PubMed |
| 42948500 | Exposure duration shapes GenX-induced transcriptomics responses in 3D HepG2/C3A spheroids. | Front Toxicol | 2026 | https://conductscience.org/library/papers/42948500 | PubMed |
| 42943327 | Mechanistic Profiling of Phenethyl Isothiocyanate in CCRF-CEM Acute Lymphoblastic Leukemia Cells. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42943327 | PubMed |
| 42943210 | Sophocarpine Inhibits Proliferation and Triggers Apoptosis in Breast Cancer Cells by Modulating the miR-21/PTEN/AKT and ERK1/2 Signaling Networks. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42943210 | PubMed |
| 42942134 | USP30 Beyond Mitophagy: A Context-Dependent Deubiquitinase in Cancer Progression. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42942134 | PubMed |
| 42942008 | PSY Inhibits Colorectal Cancer Growth and Exhibits an In Vitro Synergistic Interaction with 5-Fluorouracil. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42942008 | PubMed |
| 42930470 | Recent Advances in Fucoidan Bioactivity and Its Molecular Mechanisms in the Intervention of Vascular Cognitive Impairment. | Mar Drugs | 2026 | https://conductscience.org/library/papers/42930470 | PubMed |
| 42927612 | SIRT7 Mediated-PTEN Desuccinylation Drives Gastric Tumorigenesis by Activating PI3K/AKT Pathway. | J Biochem Mol Toxicol | 2026 | https://conductscience.org/library/papers/42927612 | PubMed |
| 42926813 | PTHrP suppresses BMP2-induced osteochondral differentiation and preserves cartilage phenotype in mesenchymal stem cells via inactivating PI3K-AKT signaling. | Genes Dis | 2027 | https://conductscience.org/library/papers/42926813 | PubMed |
| 42924596 | Mechanisms and therapeutic implications of ferritinophagy in fibrotic diseases (Review). | Int J Mol Med | 2026 | https://conductscience.org/library/papers/42924596 | PubMed |
| 42920362 | Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl-2 and Mcl-1 blockade in preclinical glioblastoma models. | FEBS Open Bio | 2026 | https://conductscience.org/library/papers/42920362 | PubMed |
| 42909819 | Gedatolisib: First Approval. | Drugs | 2026 | https://conductscience.org/library/papers/42909819 | PubMed |
| 42908866 | MKRN2 promotes gastric cancer progression by suppressing autophagy via the PI3K/Akt/mTOR signaling pathway. | Am J Cancer Res | 2026 | https://conductscience.org/library/papers/42908866 | PubMed |
| 42890088 | Signaling Pathways Mediating the Cytotoxicity of (E)-4-(1-Epoxy-7,8-propenyl)phenyl Benzoate, a Phenylpropanoid from Croton velutinus, in MCF‑7 Cells. | ACS Omega | 2026 | https://conductscience.org/library/papers/42890088 | PubMed |
| 42889412 | Epigenetic regulation of immune checkpoint signaling by microbial metabolites: mechanisms, therapeutic potential, and future perspectives. | Front Immunol | 2026 | https://conductscience.org/library/papers/42889412 | PubMed |
Genes150
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37596643
GET https://conductscience.org/api/papers/v1/37596643/authors?page=2